Retro Biosciences reaches 1.8 billion valuation
A longevity startup aiming to add ten healthy years to human lifespan has been valued at 1.8 billion dollars. Retro Biosciences, backed by OpenAI CEO Sam Altman, announced a new funding round. Its first clinical trial is already underway.
Retro Biosciences is pursuing a combination of approaches: gene therapy administered inside living people (in vivo gene therapy), replacement of cells in aging tissues, and other techniques aimed at stimulating younger, healthier cells in declining organs. The broad strategy reflects its ambition: not to target a single disease, but to slow aging itself as a biological process.
The 1.8 billion dollar valuation makes Retro one of the best-funded private companies in the longevity field. For comparison, most biotech startups only reach such valuations after successful phase 2 clinical results. Retro is still in phase 1.
What the first trial is testing
The ongoing clinical study focuses on a specific intervention, though full details about the exact treatment remain limited. What is known: the trial is tracking the safety profile of the approach in humans. Phase 1 studies are primarily designed to assess safety, not efficacy. Those results will partly determine whether Retro can deliver on its ambitions in later phases.
According to the reporting by STAT News, this funding round represents serious venture capital betting on a long-term vision. Investors are accepting the risk that evidence for effectiveness is still largely absent. That is standard in early biotech, but in the longevity field the societal and financial stakes are unusually high.
Broader context in the field
Retro is not the only player making large bets on aging biology. The field is attracting increasing capital, driven in part by demographic trends and growing scientific understanding of aging mechanisms. The question is no longer whether investors are interested, but which approaches can deliver clinical evidence. The field is still waiting for answers.